Nls pharmaceutics ceo issues letter to shareholders

Zurich, switzerland / accesswire / august 28, 2023 / nls pharmaceutics ltd. (nasdaq:nlsp, nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that its chief executive officer, alex zwyer, has issued the following letter to shareholders: nls pharmaceutics ceo issues letter to shareholders to our shareholders and friends, though we may have been quiet recently, i wanted to assure you that the team here at nls has been very busy behind the scenes ensuring that we realize our vision of awakening a brighter future for patients.
NLSP Ratings Summary
NLSP Quant Ranking